Intellia Therapeutics Stock Total Asset
| NTLA Stock | USD 15.21 0.48 3.26% |
Intellia Therapeutics fundamentals help investors to digest information that contributes to Intellia Therapeutics' financial success or failures. It also enables traders to predict the movement of Intellia Stock. The fundamental analysis module provides a way to measure Intellia Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellia Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 1.3 B | 686.6 M |
Intellia | Total Asset |
Intellia Therapeutics Company Total Asset Analysis
Intellia Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Intellia Therapeutics Total Asset | 1.3 B |
Most of Intellia Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellia Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Intellia Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Intellia Therapeutics is extremely important. It helps to project a fair market value of Intellia Stock properly, considering its historical fundamentals such as Total Asset. Since Intellia Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intellia Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intellia Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Intellia Total Asset Historical Pattern
Today, most investors in Intellia Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Intellia Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Intellia Therapeutics total asset as a starting point in their analysis.
Intellia Therapeutics Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Intellia Total Assets
Total Assets |
|
Based on the latest financial disclosure, Intellia Therapeutics has a Total Asset of 1.3 B. This is 82.7% lower than that of the Biotechnology sector and 34.16% lower than that of the Health Care industry. The total asset for all United States stocks is 95.58% higher than that of the company.
Intellia Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellia Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intellia Therapeutics could also be used in its relative valuation, which is a method of valuing Intellia Therapeutics by comparing valuation metrics of similar companies.Intellia Therapeutics is currently under evaluation in total asset category among its peers.
Intellia Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Intellia Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Intellia Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Intellia Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Intellia Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Intellia Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Intellia Therapeutics' value.| Shares | Contrarius Investment Management Ltd | 2024-09-30 | 2 M | Casdin Capital, Llc | 2024-09-30 | 2 M | Alliancebernstein L.p. | 2024-06-30 | 1.8 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-06-30 | 1.3 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.2 M | Himension Fund | 2024-06-30 | 1 M | Citadel Advisors Llc | 2024-09-30 | 989.4 K | Two Sigma Investments Llc | 2024-09-30 | 980.4 K | Ark Investment Management Llc | 2024-09-30 | 12.3 M | Vanguard Group Inc | 2024-09-30 | 9.6 M |
Intellia Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (15.89) % | ||||
| Current Valuation | 992.63 M | ||||
| Shares Outstanding | 101.85 M | ||||
| Shares Owned By Insiders | 1.20 % | ||||
| Shares Owned By Institutions | 91.38 % | ||||
| Number Of Shares Shorted | 16.37 M | ||||
| Price To Earning | (19.91) X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 35.95 X | ||||
| Revenue | 36.27 M | ||||
| Gross Profit | (367.86 M) | ||||
| EBITDA | (506.31 M) | ||||
| Net Income | (481.19 M) | ||||
| Cash And Equivalents | 874.28 M | ||||
| Cash Per Share | 11.50 X | ||||
| Total Debt | 115.35 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 7.24 X | ||||
| Book Value Per Share | 9.46 X | ||||
| Cash Flow From Operations | (394.09 M) | ||||
| Short Ratio | 5.59 X | ||||
| Earnings Per Share | (5.45) X | ||||
| Price To Earnings To Growth | (0.1) X | ||||
| Target Price | 59.78 | ||||
| Number Of Employees | 526 | ||||
| Beta | 1.81 | ||||
| Market Capitalization | 1.55 B | ||||
| Total Asset | 1.3 B | ||||
| Retained Earnings | (1.66 B) | ||||
| Working Capital | 883.12 M | ||||
| Current Asset | 77.63 M | ||||
| Current Liabilities | 10.7 M | ||||
| Net Asset | 1.3 B |
About Intellia Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intellia Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellia Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:Check out Intellia Therapeutics Piotroski F Score and Intellia Therapeutics Altman Z Score analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.